Blog

Mid-August 2026 has brought another dense wave of signals for China's innovative drug industry. Three Class 1 innovative drugs received NMPA approval in a single week——including the global-first approval of felzartamab (Jingfei®) and the world's first drug addressing FGFR inhibitor resistance in cholangiocarcinoma. AI pharma continues to evolve, with BioMap closing a multi-million dollar NewCo deal and Aureka Biotechnologies raising $100 million in Series B. GLP-1 data continues to emerge, with Ascletis' ASC30 receiving FDA Phase III clearance. Meanwhile, the $110 billion BD out-licensing boom is now being tested against actual earnings——with leading companies like BeiGene (net profit +627% YoY), Innovent (product revenue +55% YoY), and RemeGen (revenue +433% YoY) reporting strong profit growth. As the industry shifts from "BD narratives" to "earnings delivery," upstream custom synthesis demand is being driven by multiple converging factors.

August 2026 has brought a dense wave of signals for China's innovative drug industry. New drug approvals are accelerating——with multiple Class 1 drugs receiving NMPA clearance in the first ten days alone. AI pharma financing continues to heat up, with Zheyuan Tech and DeepCell announcing new rounds, while Insilico Medicine's total partnerships for 2026 approach $10 billion. GLP-1 clinical data continues to emerge, with Pfizer's ecnoglutide achieving up to 18.3% weight loss at 48 weeks and GLP-1 drugs showing a 41% reduction in obesity-related cancer risk. Meanwhile, H1 BD out-licensing deals grew 24% year-over-year, with upfront payments up 71.65%. As multiple industry drivers fire simultaneously, upstream custom synthesis demand is being pushed in new directions.